Literature DB >> 1699786

Natural killer cell activity in monoclonal gammopathies: relation to disease activity.

A Osterborg1, B Nilsson, M Björkholm, G Holm, H Mellstedt.   

Abstract

Natural killer (NK) activity and NK-related cell surface markers (CD16, CD56, CD57) of peripheral blood lymphocytes were studied in patients with multiple myeloma and MGUS (monoclonal gammopathy of undetermined significance). A strong correlation (p less than 0.0001) was found between the numbers of cells positive for the different NK cell surface markers. The proportion of CD16+ cells correlated highly to the lytic capability (lytic units/10(6) cells) of K562 cells (p less than 0.0001). High NK activity and high numbers of cells with NK-related cell surface markers were found in patients with a low tumor burden compared to controls, whereas low values were seen in patients with an advanced disease. The results indicate that NK cells might be involved in the disease process in monoclonal gammopathies, perhaps by exerting a regulatory function on the proliferating B-cell clone.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1699786     DOI： 10.1111/j.1600-0609.1990.tb00443.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


  23 in total

1.  p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Authors:  Alessandra Soriani; Cristiana Borrelli; Biancamaria Ricci; Rosa Molfetta; Alessandra Zingoni; Cinzia Fionda; Silvia Carnevale; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Giuseppe La Regina; Erica Di Cesare; Patrizia Lavia; Romano Silvestri; Rossella Paolini; Marco Cippitelli; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-12-02       Impact factor: 8.110

2.  A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Authors:  Don M Benson; Adam D Cohen; Sundar Jagannath; Nikhil C Munshi; Gary Spitzer; Craig C Hofmeister; Yvonne A Efebera; Pascale Andre; Robert Zerbib; Michael A Caligiuri
Journal:  Clin Cancer Res       Date:  2015-05-21       Impact factor: 12.531

3.  Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells.

Authors:  Fabrizio Antonangeli; Alessandra Soriani; Biancamaria Ricci; Andrea Ponzetta; Giorgia Benigni; Stefania Morrone; Giovanni Bernardini; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

4.  Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Authors:  Camille Guillerey; Lucas Ferrari de Andrade; Slavica Vuckovic; Kim Miles; Shin Foong Ngiow; Michelle C R Yong; Michele W L Teng; Marco Colonna; David S Ritchie; Marta Chesi; Martha Chesi; P Leif Bergsagel; Geoffrey R Hill; Mark J Smyth; Ludovic Martinet
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

5.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Authors:  Don M Benson; Courtney E Bakan; Anjali Mishra; Craig C Hofmeister; Yvonne Efebera; Brian Becknell; Robert A Baiocchi; Jianying Zhang; Jianhua Yu; Megan K Smith; Carli N Greenfield; Pierluigi Porcu; Steven M Devine; Rinat Rotem-Yehudar; Gerard Lozanski; John C Byrd; Michael A Caligiuri
Journal:  Blood       Date:  2010-05-11       Impact factor: 22.113

6.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

Authors:  Don M Benson; Craig C Hofmeister; Swaminathan Padmanabhan; Attaya Suvannasankha; Sundar Jagannath; Rafat Abonour; Courtney Bakan; Pascale Andre; Yvonne Efebera; Jérôme Tiollier; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

7.  Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.

Authors:  Martha Q Lacy; Sumithra Mandrekar; Angela Dispenzieri; Suzanne Hayman; Shaji Kumar; Francis Buadi; David Dingli; Mark Litzow; Peter Wettstein; Douglas Padley; Brian Kabat; Dennis Gastineau; S Vincent Rajkumar; Morie A Gertz
Journal:  Am J Hematol       Date:  2009-12       Impact factor: 10.047

Review 8.  Immunotherapy of multiple myeloma.

Authors:  Simone A Minnie; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

9.  Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

Authors:  R G Hoover; C Lary; R Page; P Travis; R Owens; J Flick; J Kornbluth; B Barlogie
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds.

Authors:  Kathryn Lagrue; Alex Carisey; David J Morgan; Rajesh Chopra; Daniel M Davis
Journal:  Blood       Date:  2015-05-22       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.